Rabbit Anti-LGALS9 Polyclonal Antibody – Cat# MBS616525

Urate Transporter 1 (LGALS9) Antibody – Rabbit Polyclonal

Name: LGALS9 Antibody; Polyclonal; Rabbit; Human-Reactive; MyBioSource
Brand: MyBioSource
SKU: MBS616525
Price: 965 USD
Availability: InStock
Rating: 5 (10 reviews)

For Research Use Only. Not for use in diagnostic procedures. Catalog #: MBS616525

Urate, a naturally occurring product of purine metabolism, is a scavenger of oxidants. Urate exists primarily as a weak acid (pKa ~5.75). Urate concentration is quite high (~200-500uM) in human due to loss of uricase gene and the presence of an effective… More details

$965 / 0.1 mg +1 FREE 8GB USB

Product Documentation

Sample Manual Insert View PDF

Testing Data View PDF

Certificate of Analysis (COA) View PDF

QC Report View PDF

Material Safety Data Sheet View PDF

Technical Datasheet View PDF

Protocol View PDF

Product Overview

Online Datasheet in PDF

Product Name

Urate Transporter 1 (LGALS9), Polyclonal Antibody

Full Product Name

Urate Transporter 1 (URAT1)

Product Gene Name

anti-LGALS9 antibody

Product Synonym Names

Anti -Urate Transporter 1 (URAT1)

Clonality

Polyclonal

Isotype

IgG

Host

Rabbit

Species Reactivity

Human

Form/Format

Supplied as a liquid in PBS, 0.1% BSA, 40% glycerol.

Purity/Purification

Affinity Purified
Purified by immunoaffinity chromatography.

Specificity

Recognizes human URAT1. Species Sequence Homology: Mouse RST/URAT1 (54%). No significant sequence homology is observed with other OAT4 or other proteins.

Preparation and Storage

May be stored at 4 degree C for short-term only. For long-term storage, aliquot and store at -20 degree C. Aliquots are stable for at least 12 months at -20 degree C. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap. Further dilutions can be made in assay buffer.

Molecular Weight

39,518 Da

Chromosome Location

chromosome: 17; Location: 17q11.2

OMIM

601879

3D Structure

ModBase 3D Structure for O00182

Immunogen

Synthetic peptide corresponding to 11aa near the C-terminus of human URAT1 (KLH). Cellular Localization: Cytoplasmic domain.

Product Categories/Family for anti-LGALS9 antibody

Antibodies; Abs to Transport Proteins

Applications Tested/Suitable for anti-LGALS9 antibody

ELISA (EL/EIA), Western Blot (WB)

Application Notes for anti-LGALS9 antibody

Suitable for use in ELISA and Western Blot.
Dilution: ELISA: 0.5-1ug/ml; Control peptide can be used to coat ELISA plates at 1ug/ml.
Western Blot: 1-10ug/ml using ECL.

Other Notes

Small volumes of anti-LGALS9 antibody vial(s) may occasionally become entrapped in the seal of the product vial during shipment and storage. If necessary, briefly centrifuge the vial on a tabletop centrifuge to dislodge any liquid in the container`s cap. Certain products may require to ship with dry ice and additional dry ice fee may apply.

Searchable Terms for LGALS9 purchase

MBS616525 is an antibody targeting LGALS9. Also known as Urate Transporter 1 (URAT1). Reactive in Human. Host: Rabbit.

Additional Details

NCBI/Uniprot data below describe general gene information for LGALS9. It may not necessarily be applicable to this product.

NCBI GI #

156622694

NCBI GeneID

3965

UniProt Primary Accession #

O00182

UniProt Secondary Accession #

O14532; O75028; Q53FQ0; Q9NQ58; A7VJG6

UniProt Related Accession #

O00182; Q3B8N1; Q53FQ0; Q8WYQ7

NCBI Official Full Name

urate transporter isoform

NCBI Official Synonym Full Names

lectin, galactoside-binding, soluble, 9

NCBI Official Symbol

LGALS9

NCBI Official Synonym Symbols

HUAT; LGALS9A; MGC117375; MGC125973; MGC125974; LGALS9

UniProt Protein Name

Galectin-9

UniProt Synonym Protein Names

Ecalectin; Tumor antigen HOM-HD-21

Protein Family

Galectin

UniProt Gene Name

LGALS9

UniProt Entry Name

LEG9_HUMAN

NCBI Protein Information

galectin-9; gal-9; ecalectin; galectin 9; OTTHUMP00000163275; tumor antigen HOM-HD-21; urate transporter/channel protein

NCBI Summary for LGALS9

The galectins are a family of beta-galactoside-binding proteins implicated in modulating cell-cell and cell-matrix interactions. The protein encoded by this gene is an S-type lectin. It is overexpressed in Hodgkin's disease tissue and might participate in the interaction between the H&RS cells with their surrounding cells and might thus play a role in the pathogenesis of this disease and/or its associated immunodeficiency. Multiple alternatively spliced transcript variants have been found for this gene. [provided by RefSeq]

UniProt Comments for LGALS9

galectin-9: Binds galactosides. Has high affinity for the Forssman pentasaccharide. May play a role in thymocyte-epithelial interactions relevant to the biology of the thymus. Inhibits cell proliferation. It is a ligand for HAVCR2/TIM3. Induces T-helper type 1 lymphocyte (Th1) death. Isoform Short acts as an eosinophil chemoattractant. 2 isoforms of the human protein are produced by alternative splicing.

Protein type: Unknown function

Chromosomal Location of Human Ortholog: 17q11.2

Cellular Component: cytoplasm

Molecular Function: signal transducer activity; galactose binding; carbohydrate binding

Biological Process: positive regulation of I-kappaB kinase/NF-kappaB cascade; signal transduction

Research Articles on LGALS9

1. galectin-9 induces osteoblast differentiation through the CD44/Smad signaling pathway in the absence of bone morphogenetic proteins.
2. Galectin-9 is a high affinity IgE-binding lectin with anti-allergic effect by blocking IgE-antigen complex formation
3. Results demonstrate that intracellular galectin-9 transactivates inflammatory cytokine genes in monocytes through direct physical interaction with NF-IL6.
4. The simultaneous expression of galectin-9 and Tim-3 may indicate an immunoregulatory function, during the ongoing cytotoxic response.
5. Transient expression of galectin-9L decreased E-selectin levels, while transient expression of galectin-9M or galectin-9S increased E-selectin levels in LoVo cells.
6. Nasopharyngeal carcinoma exosomes induce massive apoptosis in EBV-specific CD4(+) cells used as a model of target T cells. This effect is inhibited by both anti-Tim-3 and antigalectin-9 blocking antibodies.
7. the crystal structure of the human galectin-9 N-terminal carbohydrate recognition domain in complex with N-acetyllactosamine dimers and trimers.
8. decreased Gal-9 expression is inversely associated with malignant potential or differentiation of cervical cervical intraepithelial neoplasia and squamous cell carcinoma as a differentiation biomarker.
9. increase of TIM-3 expression on PBMCs, overproduction of IFN-gamma in the sera, and increased galectin-9 in PBMCs was observed in acquired aplastic anemia patients
10. Galectin-9 and galectin-1 require different glycan ligands and glycoprotein receptors to trigger T cell death.

Precautions

All of MyBioSource's Products are for scientific laboratory research purposes and are not for diagnostic, therapeutics, prophylactic or in vivo use. Through your purchase, you expressly represent and warrant to MyBioSource that you will properly test and use any Products purchased from MyBioSource in accordance with industry standards. MyBioSource and its authorized distributors reserve the right to refuse to process any order where we reasonably believe that the intended use will fall outside of our acceptable guidelines.

Disclaimer

While every efforts were made to ensure the accuracy of the information provided in this datasheet, MyBioSource will not be liable for any omissions or errors contained herein. MyBioSource reserves the right to make changes to this datasheet at any time without prior notice.

It is the responsibility of the customer to report product performance issues to MyBioSource within 30 days of receipt of the product. Please visit our Terms & Conditions page for more information.

Product Note

Select online data sheet information is drawn from bioinformatics databases, occasionally resulting in ambiguous or non-relevant product information. It is the responsibility of the customer to review, verify, and evaluate the information to make sure it matches their requirements before purchasing the kit. Our ELISA Kit assays are dynamic research tools and sometimes they may be updated and improved. If the format of this assay is important to you then please request the current manual or contact our technical support team with a presales inquiry before placing an order. We will confirm the current details of the assay. We cannot guarantee the sample manual posted online is the most current manual, it is intended to serve as an example only. Please refer to the instructions For Use provided with the assay kit for precise details.

Product PubMed Publications

Diseases associated with anti-LGALS9 antibody

Disease Name	Pubmed Publications
Neoplasms Antibodies	>23 publications with LGALS9 and Neoplasms
Inflammation Antibodies	>19 publications with LGALS9 and Inflammation
Hematologic Diseases Antibodies	>11 publications with LGALS9 and Hematologic Diseases
Carcinoma Antibodies	>9 publications with LGALS9 and Carcinoma
Leukemia Antibodies	>4 publications with LGALS9 and Leukemia
Nervous System Diseases Antibodies	>4 publications with LGALS9 and Nervous System Diseases
Colorectal Neoplasms Antibodies	>3 publications with LGALS9 and Colorectal Neoplasms
Skin Neoplasms Antibodies	>2 publications with LGALS9 and Skin Neoplasms
Breast Neoplasms Antibodies	>2 publications with LGALS9 and Breast Neoplasms
Hypertension Antibodies	>2 publications with LGALS9 and Hypertension

Organs/Tissues associated with anti-LGALS9 antibody

Organ/Tissue Name	Pubmed Publications
Blood Antibodies	>49 publications with LGALS9 and Blood
Kidney Antibodies	>11 publications with LGALS9 and Kidney
Lung Antibodies	>7 publications with LGALS9 and Lung
Liver Antibodies	>6 publications with LGALS9 and Liver
Brain Antibodies	>5 publications with LGALS9 and Brain
Bone Antibodies	>5 publications with LGALS9 and Bone
Lymph Node Antibodies	>4 publications with LGALS9 and Lymph Node
Uterus Antibodies	>4 publications with LGALS9 and Uterus
Intestine Antibodies	>4 publications with LGALS9 and Intestine
Skin Antibodies	>3 publications with LGALS9 and Skin